PART 01: Executive summary
- Highlights
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Assumptions
PART 03: Market research methodology
- Research methodology
- Economic indicators
PART 04: Introduction
- Key market highlights
PART 05: Overview of ADCs
- Antibodies
- Evolution of mAb therapeutics
- Conjugated mAbs
- History
- Key components in ADCs
- Next-generation ADCs
- Advantages
- Challenges
- Outsourcing of ADCs manufacturing
- Emergence of ADCs
- Current marketed ADCs
- PART 06: Pipeline portfolio
- Information on pipeline candidates
PART 07: Market landscape
- Market overview
- Market size and forecast
- Five forces analysis
PART 08: Market segmentation by MOA
- IgG1 antibodies
- HER2 antibodies
PART 09: Market segmentation by technologies used in ADCs
- Seattle Genetics (SGEN) technology
- ImmunoGen (IMGN) technology
- Immunomedics (IMMU) technology
PART 10: Geographical segmentation
PART 11: Market drivers
- Robust late-stage pipeline
- Rising prevalence of cancers
- Increase in demand for antibody conjugates
- Reimbursement policies
PART 12: Impact of drivers
PART 13: Market challenges
- High developmental costs
- Stringent regulations
- Risk of side effects
PART 14: Impact of drivers and challenges
PART 15: Market trends
- Strategic alliances
- Increased outsourcing of drug development
- Emergence of targeted and combination therapies
PART 16: Vendor landscape
- Competitive scenario
- Key news
- F. Hoffmann-La Roche
- Seattle Genetics
- Takeda Pharmaceuticals
PART 17: Appendix
- List of abbreviations
PART 18: Explore Technavio





List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Comparison of small molecule and mAbs
Exhibit 03: Preparation of mAbs
Exhibit 04: Timeline of ADCs
Exhibit 05: Key components
Exhibit 06: Components of next-generation ADCs
Exhibit 07: Advantages of ADCs
Exhibit 08: Emergence of ADCs
Exhibit 09: Marked ADCs products
Exhibit 10: Pipeline portfolio of ADCs
Exhibit 11: Pipeline share of ADCs
Exhibit 12: Market share of ADCs in clinical development
Exhibit 13: Few target antigens for ADCs in clinical development
Exhibit 14: Top five companies share in ADC pipeline
Exhibit 15: Global ADCs market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global ADCs market segmentation by MOA
Exhibit 18: Components in IMGN technology
Exhibit 19: Share of ADCs technologies
Exhibit 20: Global ADCs market by geography 2015
Exhibit 21: ADCs market in Americas 2015
Exhibit 22: ADCs market in Europe 2015
Exhibit 23: ADCs market in Japan 2015
Exhibit 24: Global incidence of cancer 2015 and 2020
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015
Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products
Exhibit 36: F. Hoffmann La-Roche: Key takeaways
Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline
Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs
Exhibit 40: Seattle Genetics: ADC collaborations
Exhibit 41: Seattle Genetics: Key takeaways
Exhibit 42: Takeda: Business segmentation by revenue 2015
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
Exhibit 45: Takeda Pharmaceuticals: Key takeaways